Already a Bloomberg.com user?
Sign in with the same account.
WALTHAM, Mass. (AP) — Drug developer Repligen Corp. has named a new chief financial officer, saying Jonathan Lieber's capital markets and life sciences experience will help grow the company.
Lieber is the former CFO of Xcellerex, which makes equipment for biotechnology manufacturing and was acquired by General Electric Co.'s healthcare division in May.
Lieber will shape long-term financial strategy. William Kelly, Repligen's current CFO, will become its chief accounting officer, responsible for accounting and internal controls over financial reporting.
Repligen, based in Waltham, Mass., makes and sells products used in biological drug manufacturing. It also is developing an imaging agent designed to improve the detection of pancreas problems. It hasn't posted an annual profit since the year ended in March 2009.